IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology
corporation, today announced that two of its abstracts have been
accepted for presentation at the upcoming 2019
American Society of Clinical Oncology (ASCO) Annual Meeting, which
takes place May 31 – June 4 in Chicago, IL.
“Despite advances in other cancer treatment regimens, ovarian cancer
remains a particularly difficult-to-treat disease, and one that
represents one of the most underserved areas of the treatment
landscape,” said Frederic
Ors, Chief Executive Officer at IMV. “Our presentations at ASCO
will allow us to update this important scientific audience on the
potential of DPX-Survivac monotherapy and on the progress we have made
since our groundbreaking ASCO
2018 presentation.”
Presentation details are as follows:
Poster Title: “DPX-Survivac and intermittent low-dose
cyclophosphamide (CPA) with or without epacadostat (E) in the treatment
of subjects with advanced recurrent epithelial ovarian cancer (DeCidE1
trial): T cell responses and tumor infiltration correlate with tumor
regression.”
Abstract Number: 5576
Session Title:
Gynecologic Cancer
Date and Time: June 1, 2019, 1:15 – 4:15
p.m. CT
Poster Title: “Early response assessment through multiparametric
MRI based endpoints in a phase II multicenter study evaluating the
efficacy of DPX-Survivac, intermittent low dose cyclophosphamide (CPA)
and pembrolizumab combination study in subjects with solid tumors.”
Abstract
Number: e14245
Session Title: online publication only
on May 15, 2019, 5:00 p.m. ET
ASCO will publish the official abstracts on its meeting website in
advance of the ASCO Annual Meeting at 5:00 p.m. ET on May 15. The
cut-off date for inclusion of data in the abstract was February 12,
2019. The final conference presentation will include additional data
collected between the abstract submission cutoff and the presentation
itself.
About IMV
IMV Inc. is a clinical stage biopharmaceutical company dedicated to
making immunotherapy more effective, more broadly applicable, and more
widely available to people facing cancer and other serious diseases. IMV
is pioneering a new class of immunotherapies based on the Company’s
proprietary drug delivery platform. This patented technology leverages a
novel mechanism of action that enables the programming of immune cells in
vivo, which are aimed at generating powerful new synthetic
therapeutic capabilities. IMV’s lead candidate, DPX-Survivac, is a T
cell-activating immunotherapy that combines the utility of the platform
with a target: survivin. IMV is currently assessing DPX-Survivac as a
monotherapy in advanced ovarian cancer, as well as a combination therapy
in multiple clinical studies with Merck. Connect at www.imv-inc.com.
IMV Forward-Looking Statements
This press release contains forward-looking information under
applicable securities law. All information that addresses activities or
developments that we expect to occur in the future is forward-looking
information. Forward-looking statements are based on the estimates and
opinions of management on the date the statements are made. In the press
release, such forward-looking statements include, but are not limited
to, statements regarding the FDA potentially granting accelerated
regulatory approval of DPX-Survivac. However, they should not be
regarded as a representation that any of the plans will be achieved.
Actual results may differ materially from those set forth in this press
release due to risks affecting the Corporation, including access to
capital, the successful design and completion of clinical trials and the
receipt and timely receipt of all regulatory approvals. IMV Inc. assumes
no responsibility to update forward-looking statements in this press
release except as required by law. These forward-looking statements
involve known and unknown risks and uncertainties and those risks and
uncertainties include, but are not limited to, our ability to access
capital, the successful and timely completion of clinical trials, the
receipt of all regulatory approvals and other risks detailed from time
to time in our ongoing quarterly filings and annual information form
Investors are cautioned not to rely on these forward-looking statements
and are encouraged to read IMV’s continuous disclosure documents,
including its current annual information form, as well as its audited
annual consolidated financial statements which are available on SEDAR at www.sedar.com and
on EDGAR at www.sec.gov/edgar.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190418005217/en/
Copyright Business Wire 2019